Unlocking hope: Brexanolone's impact on depression and PPD

In this video, we're going to discuss the impact of brexanolone on depression and postpartum depression. We'll cover the drug's features, side effects, and how it's been approved by the FDA.
If you're suffering from postpartum depression, then this video is for you. We'll discuss the features of brexanolone, its side effects, and how it's been approved by the FDA. We'll also discuss how brexanolone can help you fight your depression and get back on track.
Full article at: theanxiousresistance.com/f/br...
Follow along on:
Website: theanxiousresistance.com/
Facebook- / theanxiousresistance
Instagram- / theanxiousresistance
LinkedIn: / the-anxious-resistance
Pinterest: / theanxiousresistance
Twitter: / anxiousresist
Threads: www.threads.net/@theanxiousre...
Additional Mental Health Information can be found at:
nami.org/Home
mhanational.org/
www.cdc.gov/mentalhealth/lear...
www.nimh.nih.gov/health
00:00 Introduction
01:15 What is Postpartum Depression (PPD)?
03:02 What is Brexanolone?
05:28 How does Brexanolone work?
08:12 How is Brexanolone administered?
10:47 What are the side effects and considerations of Brexanolone?
14:32 Conclusion
Video Summary
1. *Introduction to Postpartum Depression (PPD):*
- PPD is a prevalent mental health condition affecting women after childbirth, characterized by symptoms like sadness, anxiety, guilt, and loss of interest. It impacts bonding with the baby and can lead to severe consequences, including an increased risk of suicide.
- Despite affecting 1 in 8 women in the United States, inadequate treatment is common due to stigma, lack of awareness, or limited access to care.
2. *Brexanolone as a Treatment for PPD:*
- Brexanolone, approved by the FDA in 2019, is an innovative medication designed specifically for treating PPD in adults. It is a synthetic form of allopregnanolone, a hormone derived from progesterone, crucial in pregnancy and childbirth.
- The drug acts on GABA-A receptors in the brain, regulating mood, stress, sleep, and cognition. It mimics allopregnanolone, aiming to restore the balance of brain chemicals and alleviate PPD symptoms.
3. *History and Development of Brexanolone:*
- Developed by Sage Therapeutics, Brexanolone originated from the research of Dr. C. Neill Epperson, who studied allopregnanolone's role in mood disorders. Clinical trials demonstrated its efficacy, leading to FDA approval in 2019.
4. *Mechanism of Action and Evidence for Use:*
- Brexanolone is a positive allosteric modulator of GABA-A receptors, acting on both synaptic and extrasynaptic receptors. Clinical trials (Study 202B and Study 202C) showed significant and rapid reduction of depressive symptoms in women with moderate to severe PPD compared to a placebo.
5. *Administration, Safety, and Considerations:*
- Brexanolone is administered as a 60-hour continuous intravenous infusion and is available under the brand name Zulresso. It is only administered in certified healthcare facilities through the Zulresso REMS Program.
- While effective, Brexanolone has potential side effects, including excessive sedation, loss of consciousness, and suicidal thoughts. The drug is expensive, and its accessibility may be limited due to cost and logistical challenges. It should be part of a comprehensive treatment plan, and its use requires careful monitoring by healthcare providers.

[@nerdbamarich2063]

Appreciate you as always 😊😊

[@TheAnxiousResistance]

As always, you're very welcome! Thanks for all your support! 😁